Greenwich LifeSciences (GLSI) vs Lifecore Biomedical (LFCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Greenwich LifeSciences (GLSI) has outperformed Lifecore Biomedical (LFCR) over the past year, gaining 32.3% versus a loss of 6.4%. Over five years, LFCR leads with a -34.5% price change compared with -60.1% for GLSI. Lifecore Biomedical is the larger company by market cap ($244.5 million vs $242.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GLSI | LFCR |
|---|---|---|
| Share price | $16.53 | $6.45 |
| Market cap | $242.63M | $244.49M |
| 1-day change | +9.18% | +0.31% |
| YTD return | -27.94% | -21.39% |
| 1-year return | +32.28% | -6.40% |
| 5-year return | -60.12% | -34.45% |
| EPS (TTM) | $-1.53 | $-1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $34.10 | $8.98 |
| 52-week low | $7.78 | $3.63 |
| Distance from 52-week high | -51.52% | -28.17% |
| Analyst consensus | none | hold |
| Avg. price target upside | +244.83% | -2.64% |
| Average volume | 138.91K | 294.61K |
| Shares outstanding | 14.68M | 37.91M |
| Employees | — | 382 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GLSI has outperformed LFCR by 38.7 percentage points over the past year.
About Greenwich LifeSciences
GLSI stock →Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.
Health Care · Biotechnology: Pharmaceutical Preparations
About Lifecore Biomedical
LFCR stock →Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities.
Health Care · Biotechnology: Pharmaceutical Preparations · 382 employees
GLSI vs LFCR FAQ
Which is bigger, Greenwich LifeSciences or Lifecore Biomedical?
Lifecore Biomedical (LFCR) is larger, with a market capitalization of $244.49M compared with $242.63M for Greenwich LifeSciences (GLSI).
Which stock has performed better over the past year, GLSI or LFCR?
GLSI returned +32.28% over the past 12 months, compared with -6.40% for LFCR (price return, excluding dividends). Past performance does not predict future results.
Are Greenwich LifeSciences and Lifecore Biomedical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.